These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34571570)

  • 21. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A
    Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.
    Martínez-Feito A; Bravo-Gallego LY; Hernández-Breijo B; Diez J; García-Ramirez L; Jaquotot M; Plasencia-Rodríguez C; Nozal P; Mezcua A; Martín-Arranz MD; Pascual-Salcedo D
    Sci Rep; 2020 Oct; 10(1):17099. PubMed ID: 33051546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018.
    Liu Y; Skup M; Yang M; Qi CZ; Wu EQ
    Adv Ther; 2022 Aug; 39(8):3711-3734. PubMed ID: 35737227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Systematic Switch From Originator Infliximab to Biosimilar Infliximab in Patients With Non-Infectious Uveitis.
    Kumar N; Follestad T; Sen HN; Austeng D
    Am J Ophthalmol; 2021 May; 225():178-184. PubMed ID: 33121931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Luber RP; O'Neill R; Singh S; Sharma E; Cunningham G; Honap S; Meade S; Ray S; Anderson SH; Mawdsley J; Sanderson JD; Samaan MA; Arkir Z; Irving PM
    Aliment Pharmacol Ther; 2021 Sep; 54(5):678-688. PubMed ID: 34223654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel approach to support implementation of biosimilars within a UK tertiary hospital.
    Saxby K; Sanghvi S; Bodalia PN; Ferner RE; Leandro M; Urquhart R; Sofat R
    Br J Clin Pharmacol; 2020 Jan; 86(1):23-28. PubMed ID: 31663154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
    Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis.
    Dapavo P; Vujic I; Fierro MT; Quaglino P; Sanlorenzo M
    J Am Acad Dermatol; 2016 Oct; 75(4):736-739. PubMed ID: 27473452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
    Mazza S; Piazza O Sed N; Conforti FS; Fascì A; Rimondi A; Marinoni B; Casini V; Ricci C; Munari F; Pirola L; Invernizzi P; Girelli C; Lupinacci G; Pastorelli L; Cavallaro F; Ferraris L; Colucci A; Amato A; Eugenio Tontini G; Vecchi M; Fiorino G; Caprioli F
    Clin Transl Sci; 2022 Jan; 15(1):172-181. PubMed ID: 34523800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study.
    Fisher A; Kim JD; Dormuth CR
    CMAJ Open; 2022; 10(1):E109-E118. PubMed ID: 35168933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease.
    Dutt K; Srinivasan A; Van Langenberg D
    BioDrugs; 2022 Sep; 36(5):639-644. PubMed ID: 35960446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Schmitz EMH; Boekema PJ; Straathof JWA; van Renswouw DC; Brunsveld L; Scharnhorst V; van de Poll MEC; Broeren MAC; Derijks LJJ
    Aliment Pharmacol Ther; 2018 Feb; 47(3):356-363. PubMed ID: 29205444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis.
    Loft N; Egeberg A; Rasmussen MK; Bryld LE; Nissen CV; Dam TN; Ajgeiy KK; Iversen L; Skov L
    JAMA Dermatol; 2021 Jun; 157(6):676-683. PubMed ID: 33825804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
    Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease.
    Kim JY; Bhat S
    Ann Pharmacother; 2022 Mar; 56(3):280-284. PubMed ID: 34192881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.